VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma

Abstract The introduction of proteasome inhibitors (PIs) into multiple myeloma (MM) treatment has substantially improved therapeutic options and survival rates. However, the development of resistance to PIs as well as serious side effects of PI treatment continue to justify the search for effective,...

Description complète

Détails bibliographiques

Auteurs principaux:	Ellen Leich-Zbat, Sofia Catalina Heredia-Guerrero, Marietheres Evers, Thorsten Stühmer, Tina Grieb, Hilka Rauert-Wunderlich, Ralf C. Bargou, Andreas Rosenwald, Manik Chatterjee, Daniela Brünnert
Format:	Artigo
Langue:	Inglês
Publié:	Nature Portfolio 2026-03-01
Collection:	Scientific Reports
Sujets:	Multiple myeloma Proteasome inhibitors PYK2 VS-4718 Carfilzomib Proteasome inhibitor resistance
Accès en ligne:	https://doi.org/10.1038/s41598-026-43205-4
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!